LPOXY Therapeutics to Acquire Key Assets from Xeno Biosciences to Advance C. difficile Infection Prevention Therapy

06 January 2025 | Monday | News

The acquisition strengthens LPOXY's pipeline with critical clinical data and intellectual property, paving the way for a pivotal Phase II study of SIDIPREV™ under FDA’s Limited Population Pathway for Antibacterial Development.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced  that it has signed a term sheet to acquire selected assets from Xeno Biosciences Inc. ("Xeno"). The assets include regulatory filings, correspondence, and documentation from FDA and global regulatory interactions, as well as comprehensive CMC data. LPOXY will benefit from ownership of data generated in Xeno's Phase I and Ib clinical trials, which validates the safety of the Active Pharmaceutical Ingredient shared by Xeno's and LPOXY's drug products. Additionally, LPOXY will acquire Xeno's intellectual property portfolio, further strengthening its proprietary position. In exchange, Xeno will become a shareholder in LPOXY Therapeutics and may receive milestone payments totaling up to $7.5 millionDennis Kim, MD, CEO of Xeno Biosciences, will join LPOXY's Board of Directors. 

LPOXY will use these assets to advance SIDIPREV™, a novel therapy aimed at preventing Clostridioides difficile infections in hospitalized patients receiving antibiotic treatment. The company plans to initiate a pivotal Phase II study under the Food and Drug Administration's (FDA) Limited Population Pathway for Antibacterial and Antifungal Development (LPAD). The LPAD pathway, established by Congress under the 21st Century Cures Act of 2016, is designed to expedite the development of therapies for serious, life-threatening infections in limited populations with unmet medical needs. C. difficile has been identified by the Centers for Disease Control and Prevention (CDC) as an urgent public health threat, contributing to more than 80 American deaths each day.

LPOXY also plans to seek Qualified Infectious Disease Product (QIDP) designation for SIDIPREV™, which would grant FDA fast-track review and an additional five years of regulatory exclusivity, extending U.S. market protection through 2045. QIDP designation was established by the GAIN (Generating Antibiotic Incentives Now) Act, included in the FDA Safety and Innovation Act (FDASIA) of 2012, to stimulate the development of treatments for drug-resistant infections.

"We are excited to advance Xeno's technology in a new therapeutic direction and to begin a pivotal Phase II study as we secure funding to support our clinical goals," said Larry Sutton, MD, PhD, founder and CEO of LPOXY Therapeutics.

Dennis Kim, MD, mentioned that: "We are enthusiastic to have LPOXY continue our legacy of delivering oxygen to the gastrointestinal tract. While Xeno wasn't able to prove that this was beneficial for weight loss, prevention of C. difficile infection is an important public health issue, and we fully support LPOXY's mission to advance this groundbreaking approach to protect vulnerable patients and save lives."

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close